CTRI/2024/03/064870招募中Unknown
A Randomized, Single dose, Double blind, Double dummy, Placebo and Active Controlled, Crossover Design Study Using Bronchoprovocation to Evaluate the Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients with Stable Mild Asthma. - NI
Intech Biopharm Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male, nonpregnant and nonlactating female subjects (20 to 65 years of age, inclusive).
- •2. A clinical diagnosis of mild asthma with historical documentation of the asthma diagnosis according to either (1) the National Asthma Education and Prevention Program (NAEPP) guidelines (2007) or (2) the Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention (2020).
- •3. Stable mild asthma receiving the following required inhaled medications for at least 1 month prior to screening Low doses of ICS alone, or in combination with SABA, used regularly with a stable regimen.
- •4. Forced Expiratory Volume in 1 second (FEV1) greater than or equal to 80 percentage of the local predicted normal value after withholding SABA greater than or equal to 8 hours.
- •5. Airway responsiveness to methacholine demonstrated by a pre albuterol dose (baseline) PC20 smaller than or equal to 8 mg per mL.
- •6. Nonsmoker for at least 6 months prior to the study and a maximum smoking history of 5 pack years (the equivalent of one pack per day for 5 years).
- •7. Provision of written informed consent.
- •8. Other than asthma, in general good health.
- •9. Body mass index (BMI) between 17 and 35 kg per m2 (inclusive).
- •10. Able to correctly use MDI inhalers.
- •11. Able to perform valid and reproducible pulmonary function tests including no evidence of spirometry effort induced bronchoconstriction.
- •12. If the subject or subjects partner is of childbearing potential, a medically acceptable form of contraception will be used for the duration of the study. Medically acceptable contraceptives including (1) surgical sterilization, (2) Health Authority approved female hormonal contraceptives, (3) an intrauterine device (IUD), (4) condoms with spermicide, or (5) diaphragm with spermicide.
排除标准
- •1. Evidence of conditions altering airway reactivity to methacholine, including upper or lower respiratory tract infections (e.g., pneumonia, viral bronchitis, allergic rhinitis, sinobronchitis, etc.) within 6 weeks before Screening.
- •2. Evidence of a baseline FEV1 less than 60 percentage of the local predicted normal value or FEV1 less than 1.5 L.
- •3. History of seasonal asthma exacerbations, in which case the subject should be studied outside of the relevant allergen season.
- •4. History of cystic fibrosis, bronchiectasis, COPD, or other respiratory diseases including COPD, chronic bronchitis, emphysema, tuberculosis, pulmonary carcinoma, pulmonary fibrosis, pulmonary hypertension that, in the opinion of the Investigator, would compromise subject safety or interfere with the evaluations.
- •5. History of cardiovascular, hematological, renal, neurologic, hepatic, psychiatric, endocrine dysfunction, including ECG with evidence of ischemic heart diseases and significant arrhythmias.
- •6. Treatment in an emergency room or hospitalization for acute asthmatic symptoms within 3 months prior to screening.
- •7. Known intolerance or hypersensitivity to any component of the albuterol MDI, beta2 receptor-agonist drug, HFA, any related compounds or methacholine.
- •8. Need for daily oral corticosteroids within 3 months prior to screening.
- •9. Cardiac arrhythmia or 12 lead electrocardiogram (ECG) abnormalities, that in the opinion of the Investigator would compromise subject safety or interfere with the evaluations, or a QTc more than 440 ms for males and more than 460 ms for females using Fredericia formula.
- •10. Subjects receiving beta blocker via any route or who may require beta blockers during the study.
- •11. History of narrow angle glaucoma, convulsive disorders, hyperthyroidism, uncontrolled diabetes, paradoxical bronchospasm.
- •12. History of malignancies.
- •13. History of alcohol or drug abuse.
- •14. Eye, brain, thoracic, and abdominal surgeries within 3 months prior to screening.
- •15. Use of cromyolyn, leukotriene receptor antagonists (LTRA), nedocromil, zileuton, theophylline, or long-acting beta-agonists (LABA) within 1 month prior to screening.
- •16. History of receiving muscarinic beta2-agonists (MABAs), short acting muscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), anti-IgE, anti-IL5/5R, anti-IL4R, high dose, or systemic corticosteroid for treatment of asthma within 6 months prior to screening.
- •17. Known Human Immunodeficiency Virus (HIV)-positive status.
- •18. Participated in any interventional clinical trials within 1 month prior to screening.
- •19. Pregnancy or breast feeding.
研究者
相似试验
进行中（未招募）
不适用
A single dose, randomized, double blind, double dummy, placebo controlled, three-period crossover clinical study, comparing the onset of relief from methacholine induced bronchoconstriction with fixed combination beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/actuation pMDI with HFA-134a propellant (Foster) versus standard salbutamol pMDI 100 µg/actuation (Ventolin Evohaler) therapy in asthmatic patients. - MART 1 Maintenance And Reliever TherapyAshtmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2008-000905-12-ITCHIESI
进行中（未招募）
不适用
A single dose, randomized, double blind, double dummy, placebo controlled, three-period crossover clinical study, comparing the onset of relief from methacholine induced bronchoconstriction with fixed combination beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/actuation pMDI with HFA-134a propellant (Foster®) versus standard salbutamol pMDI 100 µg/actuation (Ventolin® 100 µg) therapy in asthmatic patients - MART1AsthmaEUCTR2008-000905-12-GBCHIESI FARMACEUTICI S.p.A.54
进行中（未招募）
不适用
A single dose, randomised, double blind, double dummy, placebo-controlled, three-period crossover clinical study, comparing the efficacy, safety and tolerability of Formoterol-HFA pMDI 12 microgram per actuation administered by means of a spacer device (AeroChamber Plus) with that of Formoterol-HFA pMDI 12 microgram per actuation in 5- to 12-year-old children with persistent moderate to severe asthmaPersistent moderate to severe childhood asthma (5 to 12 years of age, inclusive)MedDRA version: 8.1Level: PTClassification code 10049585EUCTR2006-000907-41-HUChiesi Farmaceutici S.p.A.42
进行中（未招募）
1 期
A clinical trial to investigate the comparability of relief from methacholine-induced bronchoconstriction with CHF1535 100/6 µg NEXThaler® versus CHF1535 100/6 µg pMDI in asthmatic patients.MedDRA version: 19.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-003672-47-GBChiesi Farmaceutici S.p.A.60
已完成
不适用
Pharmacokinetics of Vitamin C Sustained ReleaseTablets 500 mgCTRI/2021/02/031421Inventia Healthcare Limited18